|
Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis |
Ferrandiz C, Garcia A, Blasco AJ, Lazaro P |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Ferrandiz C, Garcia A, Blasco AJ, Lazaro P. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology 2012; 26(6): 768-777 Indexing Status Subject indexing assigned by NLM MeSH Adalimumab; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized /economics /therapeutic use; Cost-Benefit Analysis; Dermatologic Agents /economics /therapeutic use; Etanercept; Humans; Immunoglobulin G /economics /therapeutic use; Infliximab; Psoriasis /drug therapy; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor /therapeutic use; Ustekinumab AccessionNumber 22012023257 Date bibliographic record published 03/01/2013 |
|
|
|